Abstract
Biotechnology has already exerted a major impact in the management of cardiovascular disorders by providing such drugs as tissue plasminogen activator (t-PA), urokinase, platelet targeting antibodies, recombinant anticoagulant agents such as hirudin and various modulatory proteins. On the diagnostic front, biotechnology has provided newer, more sensitive methods to detect minute changes in blood for the proper diagnosis and management of cardiovascular disorders. Several major breakthroughs in both the diagnosis and treatment of cardiovascular disorders have recently occurred. The measurement of troponin T and I in circulating blood provides a reliable measure of myocardial damage. Other analytes have also been identified for the rapid diagnosis of cardiovascular disorders. Such agents as tissue factor pathway inhibitor (TFPI), protein and antithrombin III have been developed and may prove to be useful in the management of antithrombotic disorders. Although the use of transgenic animals is still at experimental stages, the initial findings are promising and will provide important leads into the development of therapeutic proteins. Through biotechnology, recombinant inhibitors of fibrinolysis have also been developed and may be useful in the management of bleeding disorders. Nucleic acid derived drugs have been used for sometime. Several newer nucleic acid derivatives have been recently developed. An important consideration in the use of biotechnology derived drugs is the availability of a US Pharmacopoeial monograph on specific drugs. The subject of providing a monograph on biotechnology derived drugs is now being dealt with by the USP. Several other considerations in the development, clinical applications and the results of clinical trials on new biotechnology derived drugs are being addressed at this time. It is hoped that the impact of biotechnology on the diagnosis and treatment of cardiovascular disorders will result in a significant change in the management of these disorders.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Adams, J.E., Bodor, G.S., Davila-Roman, V.G., Delmex, J.A., Apple, F.S., Hadenson, J.H. and Jaffe, A.S., 1993, Cardiac Troponin I — A marker with high specificity for cardiac injury, Circulation 88:101–106.
Bauer, K.A. and Rosenberg, R.D., 1987. The pathophysiology of the prothrombotic state in humans: Insights gained from studies using markers of hemostatic system activation. Blood 70:343–350.
Broze, G., Warren, J. and Novotnym L.A., 1988. The lipoprotein associated coagulation inhibitor that inhibits the factor VIIa-tissue factor complex also inhibits factors Xa: Insight into its possible mechanism of action, Blood 71:335–343.
Farced, J., 1981, New methods in hemostatic testing. 1981, Perspectives in hemostasis. in “Perspectives in Hemostasis”. J. Fareed, ed., Pergamon Press, New York. NY.
Fareed, J., Walenga, J.M. and Breddin, K., 1989. Newer avenues in antithrombotic therapy, Semin. Thromb. Hcmost. 15.
Fareed, J., Walenga, J.M. and Hoppensteadt, D.A., 1988. Pharmacologic profiling of defibrotide in experimental models. Semin., Thromb. Hemost. 14:27–37.
Fareed, J., Walenga, J.M. and Iyer, L. 1991. An objective perspective on recombinant hirudin: A new anticoagulant and antithrombotic agent. Blood Coag. Fibrinoly 2:135–148.
Fareed, J., Hoppensteadt, D., Walenga J.M. and Pifarre, R., 1993. New antithrombotic drugs for myocardial infarction in “Anticoagulation, Hemostasis and Blood Preservation in Cardiovascular Surgery”, R. Pifarre. ed., Hanley & Belfus. Philadelphia.
Fareed, J., 1993a, Recombinant antithrombotic drugs. Impact on the management of thrombotic disorders in the 1990s. Proceedings in the International Biotechnology Exposition and Scientific Conference 1993), San Francisco. CA. pp. 50. 51. Cartlidge Associates. Belmont, CA.
Fareed, J., Hoppensteadt, D., Walenga, J.M. and Bick, R.L., 1994, Current trends in the development of anticoagulant and antithrombotic drugs, Med. Clin. No. America 78:713–731.
Fareed, J., 1994a, Proceedings of the International Biotechnology Exposition and Scientific Conference (IBEX 1994), San Francisco. CA. PP. 44. 46. 49. 50. 55. 67, Cartlidge Associates, Belmont, CA.
Faxon, D.P., Sanborn, T.A. and Haudenschild, C.C., 1984, Effect of antiplatelet therapy on restenosis after experimental angioplasty. Am. J. Cardiol. 53:72C–76C.
Hake, U., Schmid, F.X., Iversen, S., Dahm, M., Mayer, E., Hafner, G. and Oelert, H., 1993, Troponin T — a reliable marker of perioperative myocardial infarction? Eur. J. Cardiothorac. Surg. 7:628–633.
Piascik, M.M., 1991. Research and development of drugs and biologic entities. Am. J. Hosp. Pharm. 48(10):S 4–13.
Sidoli, A., Galliani, S. and Baralle, F.E., 1990. DNA based diagnostic tests: Recombinant DNA and cardiovascular disease risk factors. Br. Med. Bulletin 46(4):941–959.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Fareed, J., Hoppensteadt, D., Iyer, L., Koza, M., Walenga, J.M., Bermes, E. (1995). Impact of Biotechnology in the Diagnostic and Therapeutic Management of Cardiovascular Disorders. In: Longenecker, J.B., Kritchevsky, D., Drezner, M.K. (eds) Nutrition and Biotechnology in Heart Disease and Cancer. Advances in Experimental Medicine and Biology, vol 369. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1957-7_10
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1957-7_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5804-6
Online ISBN: 978-1-4615-1957-7
eBook Packages: Springer Book Archive